Atlas Trials

Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease

Clinical trial NCT05098028 · COMPLETED

Trial details

NCT number
NCT05098028
Sponsor
Bausch Health Americas, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Sickle Cell Disease
Start date
2022-03-22
Primary completion
2023-09-04
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.